Startseite>>Signaling Pathways>> GPCR/G protein>> CCR>>CCR6 inhibitor 1

CCR6 inhibitor 1

Katalog-Nr.GC34521

CCR6-Inhibitor 1 ist ein potenter und selektiver CCR6-Inhibitor mit IC50-Werten von 0,45 und 6 nM fÜr Affen- und Human-CCR6, viel selektiver bei CCR6 gegenÜber humanem CCR1 (IC50, > 30000 nM) und CCR7 (IC50, 9400 nM).

Products are for research use only. Not for human use. We do not sell to patients.

CCR6 inhibitor 1 Chemische Struktur

Cas No.: 2437547-04-9

Größe Preis Lagerbestand Menge
10mM (in 1mL DMSO)
464,00 $
Auf Lager
5mg
417,00 $
Auf Lager
10mg
695,00 $
Auf Lager
50mg
1.808,00 $
Auf Lager
100mg
3.059,00 $
Auf Lager

Tel:(909) 407-4943 Email: sales@glpbio.com

Kundenbewertungen

Basiert auf Kundenrezensionen.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

CCR6 inhibitor 1 is a potent and selective CCR6 inhibitor, with IC50s of 0.45 and 6 nM for monkey and human CCR6, much more selective at CCR6 over human CCR1 (IC50, > 30000 nM), and CCR7 (IC50, 9400 nM). CCR6 inhibitor 1 markedly blocks ERK phosphorylation. CCR6 inhibitor 1 is used in the research of autoimmune diseases and cancer[1]. Moneky CCR6|0.45 nM (IC50)|Human CCR6|6 nM (IC50)|Human CCR7|9400 nM (IC50)

CCR6 inhibitor 1 (Compound 35) inhibits L20-induced human B cell migration[1].

[1]. Tawaraishi T, et al. Identification of a novel series of potent and selective CCR6 inhibitors as biological probes. Bioorg Med Chem Lett. 2018 Oct 1;28(18):3067-3072.

Bewertungen

Review for CCR6 inhibitor 1

Average Rating: 5 ★★★★★ (Based on Reviews and 30 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for CCR6 inhibitor 1

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.